Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indobufen + clopidogrel in intracranial artery stenting
ChiCTR2500098014Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Feb 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Indobufen and clopidogrel in brain aneurysm (IA), Cerebral atherosclerotic stenosis (ICAD) and Intracranial artery occlusion (ICAO), sponsored by Beijing Hospital. Primary endpoint: New ischemic stroke or TIA events. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
Indobufenclopidogrel
03
Conditions
brain aneurysm (IA)Cerebral atherosclerotic stenosis (ICAD)Intracranial artery occlusion (ICAO)
Beyond the preview
Go deeper on ChiCTR2500098014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098014.